<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:media="http://search.yahoo.com/mrss/">
  <channel>
    <title>Monoclonal antibody</title>
    <description>
      <![CDATA[]]>
    </description>
    <link>https://www.bioworld.com/rss</link>
    <language>en-us</language>
    <item>
      <title>Biogen amasses full felzartamab rights with $850M TJ deal </title>
      <description>
        <![CDATA[Biogen Inc. has consolidated full global rights to felzartamab through an $850 million deal with TJ Biopharma Co. Ltd. April 20, closing the chapter on a complex 10-year license saga. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/730485</guid>
      <pubDate>Tue, 21 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730485-biogen-amasses-full-felzartamab-rights-with-850m-tj-deal</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Global-handshake-silhouette.webp?t=1670353285" type="image/png" medium="image" fileSize="178881">
        <media:title type="plain">Global handshake silhouette</media:title>
      </media:content>
    </item>
    <item>
      <title>Alethio unveils ATX-011 for essential thrombocythemia</title>
      <description>
        <![CDATA[Alethio Therapeutics Inc. has unveiled ATX-011, a mutation-agnostic antibody for essential thrombocythemia. ATX-011 is a potential first-in-class monoclonal antibody based on a new target identified on mutant stem cells that drive myeloproliferative neoplasm disease progression.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730427</guid>
      <pubDate>Thu, 16 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730427-alethio-unveils-atx-011-for-essential-thrombocythemia</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Hematologic/Blood-platelet-clotting-bleeding-disorders.webp?t=1770393040" type="image/jpeg" medium="image" fileSize="595184">
        <media:title type="plain">3D illustration of platelets in the boodstream</media:title>
      </media:content>
    </item>
    <item>
      <title>Spyre’s SPY-001 induces better outcomes in ulcerative colitis</title>
      <description>
        <![CDATA[Spyre Therapeutics Inc. is off to a good start in its goal to create the best combination therapy for inflammatory bowel disease, a group of chronic, relapsing autoimmune conditions of the digestive tract that encompasses Crohn’s disease and ulcerative colitis. The Waltham, Mass.-based company estimates the market for IBD is currently at approximately $25 billion but will jump to around $40 billion in 2030.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730280</guid>
      <pubDate>Mon, 13 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730280-spyres-spy-001-induces-better-outcomes-in-ulcerative-colitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/Ulcerative-colitis-illustration.webp?t=1776115680" type="image/jpeg" medium="image" fileSize="312045">
        <media:title type="plain">Ulcerative colitis</media:title>
      </media:content>
    </item>
    <item>
      <title>Invivyd unveils measles monoclonal antibody candidate VMS-063</title>
      <description>
        <![CDATA[Invivyd Inc. has announced the discovery and advancement of VMS-063, a novel monoclonal antibody candidate for the treatment and prevention of measles.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730261</guid>
      <pubDate>Fri, 10 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730261-invivyd-unveils-measles-monoclonal-antibody-candidate-vms-063</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Infectious/Infection-measles-rash.webp?t=1775834424" type="image/jpeg" medium="image" fileSize="715450">
        <media:title type="plain">Photo of measles rash on skin</media:title>
      </media:content>
    </item>
    <item>
      <title>Ibio’s IBIO-600 cleared to enter clinic in Australia for obesity</title>
      <description>
        <![CDATA[Ibio Inc. has received clinical trial notification (CTN) acknowledgement from Australia’s Therapeutic Goods Administration (TGA), as well as Human Research Ethics Committee approval, for IBIO-600, enabling the initiation of a first-in-human trial in Australia.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730241</guid>
      <pubDate>Thu, 09 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730241-ibios-ibio-600-cleared-to-enter-clinic-in-australia-for-obesity</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Obesity/obesity-weight-loss.webp?t=1589291248" type="image/png" medium="image" fileSize="590446">
        <media:title type="plain">Tape measure, apple on scale</media:title>
      </media:content>
    </item>
    <item>
      <title>Five-drug VIPOR regimen shows promise in aggressive blood cancer </title>
      <description>
        <![CDATA[Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730204</guid>
      <pubDate>Tue, 07 Apr 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730204-five-drug-vipor-regimen-shows-promise-in-aggressive-blood-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/ICKSH_ViPOR-scans-4-1.webp?t=1775073716" type="image/jpeg" medium="image" fileSize="427849">
        <media:title type="plain">PET scans showing before and after treatment with VIPOR</media:title>
        <media:description type="plain">Before (top) and after (bottom) treatment with VIPOR. Full-body and cross-sectional PET scans of a patient show large lymphoma tumors (circled in red) that have disappeared with treatment. Credit: Center for Cancer Research/National Cancer Institute</media:description>
      </media:content>
    </item>
    <item>
      <title>Longhorn reports long-acting peptidoglycan-targeted mAb for sepsis</title>
      <description>
        <![CDATA[At the World Vaccine Congress this week, Longhorn Vaccines & Diagnostics LLC presented the preclinical characterization of LHNVD-501, a half-life-extended, humanized IgG monoclonal antibody (mAb) targeting peptidoglycan (PGN). PGN is a conserved structural component shared across bacterial species and an upstream driver of sepsis, as well as metabolic disease, autoimmune disorders and neurodegeneration.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730094</guid>
      <pubDate>Thu, 02 Apr 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730094-longhorn-reports-long-acting-peptidoglycan-targeted-mab-for-sepsis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/Monoclonal-antibody-therapy.webp?t=1731516507" type="image/jpeg" medium="image" fileSize="136228">
        <media:title type="plain">Illustration of monoclonal antibody hovering between doctor's hands</media:title>
      </media:content>
    </item>
    <item>
      <title>Five-drug VIPOR regimen shows promise in aggressive blood cancer </title>
      <description>
        <![CDATA[Deep molecular advances are enabling precision medicine for the field of hematology, Wyndham Wilson said during a plenary session at the 2026 Korean Society of Hematology International Conference March 26.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729980</guid>
      <pubDate>Wed, 01 Apr 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729980-five-drug-vipor-regimen-shows-promise-in-aggressive-blood-cancer</link>
      <media:content url="https://www.bioworld.com/ext/resources/BW-source/2026/ICKSH_ViPOR-scans-4-1.webp?t=1775073716" type="image/jpeg" medium="image" fileSize="427849">
        <media:title type="plain">PET scans showing before and after treatment with VIPOR</media:title>
        <media:description type="plain">Before (top) and after (bottom) treatment with VIPOR. Full-body and cross-sectional PET scans of a patient show large lymphoma tumors (circled in red) that have disappeared with treatment. Credit: Center for Cancer Research/National Cancer Institute</media:description>
      </media:content>
    </item>
    <item>
      <title>Simcere’s rademikibart meets phase III endpoints in atopic dermatitis </title>
      <description>
        <![CDATA[Simcere Pharmaceutical Group Ltd.’s monoclonal antibody, rademikibart (CBP-201), met the primary endpoint in a Chinese phase III study in adults and adolescents with moderate to severe atopic dermatitis. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729969</guid>
      <pubDate>Tue, 31 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729969-simceres-rademikibart-meets-phase-iii-endpoints-in-atopic-dermatitis</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Drugs/monoclonal-antibody-mab.webp?t=1713364043" type="image/jpeg" medium="image" fileSize="243312">
        <media:title type="plain">Monoclonal antibody illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Tyligand Bioscience divulges new dual-drug antibody-drug conjugates</title>
      <description>
        <![CDATA[Tyligand Bioscience Ltd. has reported new dual-drug antibody-drug conjugates comprising monoclonal antibodies covalently linked to stimulator of interferon genes protein (STING; TMEM173) agonist and a cytotoxic drug.]]>
      </description>
      <guid>http://www.bioworld.com/articles/730048</guid>
      <pubDate>Tue, 31 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/730048-tyligand-bioscience-divulges-new-dual-drug-antibody-drug-conjugates</link>
    </item>
    <item>
      <title>Novartis buying allergy firm Excellergy for $2B</title>
      <description>
        <![CDATA[Just five months after raising a $70 million series A round, newly launched Excellergy Inc. agreed to a $2 billion M&A transaction that would bring its trifunctional allergic effector cell response inhibitors (ECRIs) to Novartis AG.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729915</guid>
      <pubDate>Fri, 27 Mar 2026 08:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729915-novartis-buying-allergy-firm-excellergy-for-2b</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Handshake-dollar-sign.webp?t=1593036546" type="image/png" medium="image" fileSize="515569">
        <media:title type="plain">Handshake dollar sign</media:title>
      </media:content>
    </item>
    <item>
      <title>Gilead pens dual-purpose $2B Ouro M&amp;A deal with Galapagos </title>
      <description>
        <![CDATA[Gilead Sciences Inc. said after U.S. market close March 23 that it will acquire privately held Ouro Medicines LLC and its autoimmune BCMA/CD3 bispecific T-cell engager, gamgertamig, in a deal valued at $2.17 billion.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729829</guid>
      <pubDate>Tue, 24 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729829-gilead-pens-dual-purpose-2b-ouro-m-and-a-deal-with-galapagos</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Hands-and-gears.webp?t=1590606316" type="image/png" medium="image" fileSize="377385">
        <media:title type="plain">Hands holding gears</media:title>
      </media:content>
    </item>
    <item>
      <title>Acumen reports new Aβ oligomer-targeting antibodies for Alzheimer’s</title>
      <description>
        <![CDATA[Soluble amyloid-β oligomers (AβOs) are known early drivers of Alzheimer’s disease pathogenesis. Acumen Pharmaceuticals Inc. has recently presented data generated in the development and characterization of anti-AβO antibodies with high selectivity for AβO over Aβ monomers.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729859</guid>
      <pubDate>Tue, 24 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729859-acumen-reports-new-a-oligomer-targeting-antibodies-for-alzheimers</link>
    </item>
    <item>
      <title>Liminatus eyes clinic with CD47-blockade antibody IBA-101</title>
      <description>
        <![CDATA[Liminatus Pharma Inc. has announced plans to conduct a phase I trial of IBA-101, a next-generation CD47-blockade antibody designed to work alongside PD-1/PD-L1 checkpoint inhibitors across a range of solid tumors.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729692</guid>
      <pubDate>Wed, 18 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729692-liminatus-eyes-clinic-with-cd47-blockade-antibody-iba-101</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Drug-research-illustration.webp?t=1711382891" type="image/jpeg" medium="image" fileSize="249152">
        <media:title type="plain">Drug discovery illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Series A financing at VST Bio to advance VB-001 into clinic</title>
      <description>
        <![CDATA[VST Bio Corp. has closed its series A financing designed to support the company’s work in vascular diseases with the development of first-in-class antibodies targeting edema and inflammation for patients with ischemic stroke.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729690</guid>
      <pubDate>Wed, 18 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729690-series-a-financing-at-vst-bio-to-advance-vb-001-into-clinic</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Deals-and-MAs/Deal-illustration.webp?t=1755091469" type="image/png" medium="image" fileSize="522090">
        <media:title type="plain">Doctor with brain illustration, businessman with dollar sign illustration</media:title>
      </media:content>
    </item>
    <item>
      <title>Pharma USA: The complex journey of launching rare disease drugs</title>
      <description>
        <![CDATA[Rare disease drug development companies battle with economic challenges and small patient populations, but new technology alongside a human connection are helping researchers and marketers identify patients, educate physicians and build networks. At Pharma USA, a Reuters Events meeting in Philadelphia March 16-17, executives from Astrazeneca plc and UCB SA discussed their successes with rare disease launches, presenting their playbooks for building trust and driving adoption among patients.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729546</guid>
      <pubDate>Tue, 17 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729546-pharma-usa-the-complex-journey-of-launching-rare-disease-drugs</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Research-and-science/Biopharma-research-illustration.webp?t=1773784516" type="image/jpeg" medium="image" fileSize="838384">
        <media:title type="plain">Biopharma research illustration with pill, DNA, microscope, data</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Qyuns moves IL-17 biologic toward first approval</title>
      <description>
        <![CDATA[Qyuns Therapeutics Co. Ltd. has moved closer to its first commercial product after China’s National Medical Products Administration (NMPA) accepted its NDA for IL-17 antibody crusekitug (QX-002N) for treating ankylosing spondylitis (AS), a chronic inflammatory disease that affects the spine and sacroiliac joints.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729710</guid>
      <pubDate>Tue, 17 Mar 2026 11:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729710-chinas-qyuns-moves-il-17-biologic-toward-first-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Inflamed-Lumbar-Spine-Disc.webp?t=1773260221" type="image/jpeg" medium="image" fileSize="666699">
        <media:title type="plain">Illustration of inflamed spine</media:title>
      </media:content>
    </item>
    <item>
      <title>Excellergy presents data on effector cell response inhibitor Exl-111</title>
      <description>
        <![CDATA[Excellergy Inc. has presented data for Exl-111, an investigational allergic effector cell response inhibitor (ECRI) targeting the IgE axis that is designed to disarm allergic effector cells at the source of activation.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729649</guid>
      <pubDate>Mon, 16 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729649-excellergy-presents-data-on-effector-cell-response-inhibitor-exl-111</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/Science-research-structures-microscope.webp?t=1682529172" type="image/png" medium="image" fileSize="579163">
        <media:title type="plain">Drug R&amp;D concept image.</media:title>
      </media:content>
    </item>
    <item>
      <title>UK sets out regulatory pathway for biologics made in space</title>
      <description>
        <![CDATA[U.K. biopharma is working with the country’s space agency and Civil Aviation Authority (CAA) to plot a route for manufacturing biologic drugs in low earth orbit. ]]>
      </description>
      <guid>http://www.bioworld.com/articles/729480</guid>
      <pubDate>Thu, 12 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729480-uk-sets-out-regulatory-pathway-for-biologics-made-in-space</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Misc/planet-earth-space-europe.webp?t=1773347341" type="image/jpeg" medium="image" fileSize="1122080">
        <media:title type="plain">Earth from space</media:title>
      </media:content>
    </item>
    <item>
      <title>China’s Qyuns moves IL-17 biologic toward first approval</title>
      <description>
        <![CDATA[Qyuns Therapeutics Co. Ltd. has moved closer to its first commercial product after China’s National Medical Products Administration (NMPA) accepted its NDA for IL-17 antibody crusekitug (QX-002N) for treating ankylosing spondylitis (AS), a chronic inflammatory disease that affects the spine and sacroiliac joints.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729467</guid>
      <pubDate>Wed, 11 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729467-chinas-qyuns-moves-il-17-biologic-toward-first-approval</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Musculoskeletal/Inflamed-Lumbar-Spine-Disc.webp?t=1773260221" type="image/jpeg" medium="image" fileSize="666699">
        <media:title type="plain">Illustration of inflamed spine</media:title>
      </media:content>
    </item>
    <item>
      <title>Counterx signs license supporting work in fentanyl overdose</title>
      <description>
        <![CDATA[Counterx Therapeutics Inc. has executed an exclusive licensing agreement with the University of Minnesota and the University of Washington for a portfolio of novel monoclonal antibody and vaccine candidates targeting fentanyl and opioid overdose.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729590</guid>
      <pubDate>Wed, 11 Mar 2026 09:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729590-counterx-signs-license-supporting-work-in-fentanyl-overdose</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Misc/Substance-use-opioids-overdose.webp?t=1690469144" type="image/jpeg" medium="image" fileSize="278724">
        <media:title type="plain">Various pills and powders in small plastic ziplock bags</media:title>
      </media:content>
    </item>
    <item>
      <title>Kyowa Kirin discontinues rocatinlimab trials due to safety issues</title>
      <description>
        <![CDATA[Shortly after Amgen Inc. walked away from its partnership with Kyowa Kirin Co. Ltd., the Tokyo-based company said it is discontinuing all ongoing clinical trials for rocatinlimab due to safety concerns.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729583</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729583-kyowa-kirin-discontinues-rocatinlimab-trials-due-to-safety-issues</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Lab-vials.webp?t=1588276131" type="image/png" medium="image" fileSize="364754">
        <media:title type="plain">Lab vials and dropper</media:title>
      </media:content>
    </item>
    <item>
      <title>Telix advances PSMA radiotherapy challenger to Pluvicto</title>
      <description>
        <![CDATA[Australia’s Telix Pharmaceuticals Ltd. is advancing a potential challenger to Novartis plc’s dominant prostate cancer radioligand therapy, Pluvicto (lutetium [177Lu] vipivotide tetraxetan), after reporting that the safety lead-in portion of its global phase III Prostact trial met its primary objectives.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729455</guid>
      <pubDate>Tue, 10 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729455-telix-advances-psma-radiotherapy-challenger-to-pluvicto</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Cancer/Prostate-cancer-cells.webp?t=1765920543" type="image/png" medium="image" fileSize="389611">
        <media:title type="plain">Prostate cancer cells</media:title>
        <media:description type="plain">Prostate cancer cells</media:description>
      </media:content>
    </item>
    <item>
      <title>Dianthus in the pink as claseprubart CIDP phase III Captivates</title>
      <description>
        <![CDATA[As soon as Dianthus Therapeutics Inc. disclosed its early “go” decision on claseprubart in chronic inflammatory demyelinating polyneuropathy (CIDP), Wall Street set about comparing the phase III monoclonal antibody (mAb) to other prospects in the space, with particular focus on Sanofi SA’s riliprubart (SAR-455088).]]>
      </description>
      <guid>http://www.bioworld.com/articles/729435</guid>
      <pubDate>Mon, 09 Mar 2026 12:00:00 -0400</pubDate>
      <link>https://www.bioworld.com/articles/729435-dianthus-in-the-pink-as-claseprubart-cidp-phase-iii-captivates</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Neuron-destruction-of-myelin.webp?t=1750949355" type="image/jpeg" medium="image" fileSize="282213">
        <media:title type="plain">3D illustration demonstrating inflammation and scarring of the myelin sheath</media:title>
      </media:content>
    </item>
    <item>
      <title>Kyowa Kirin discontinues rocatinlimab trials due to safety issues</title>
      <description>
        <![CDATA[Shortly after Amgen Inc. walked away from its partnership with Kyowa Kirin Co. Ltd., the Tokyo-based company said it is discontinuing all ongoing clinical trials for rocatinlimab due to safety concerns.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729343</guid>
      <pubDate>Thu, 05 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729343-kyowa-kirin-discontinues-rocatinlimab-trials-due-to-safety-issues</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Clinics/Lab-vials.webp?t=1588276131" type="image/png" medium="image" fileSize="364754">
        <media:title type="plain">Lab vials and dropper</media:title>
      </media:content>
    </item>
    <item>
      <title>Boehringer drops OSE’s cancer drug in MASH, where GLP-1s march on </title>
      <description>
        <![CDATA[Boehringer Ingelheim GmbH is stopping development of OSE Immunotherapeutics SA’s BI-770371 in metabolic dysfunction-associated steatohepatitis (MASH), after the SIRPα antagonist failed to show efficacy in a phase II study. Codevelopment of BI-770371 will continue for oncology indications, however, which was the initial target of the duo’s €1.4 billion (US$1.6 million) partnership in 2018.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729286</guid>
      <pubDate>Tue, 03 Mar 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729286-boehringer-drops-oses-cancer-drug-in-mash-where-glp-1s-march-on</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Gastrointestinal/fatty-liver-disease.webp?t=1589217291" type="image/png" medium="image" fileSize="932342">
        <media:title type="plain">Liver disease</media:title>
      </media:content>
    </item>
    <item>
      <title>TSLP still plays well, Generates $400M IPO </title>
      <description>
        <![CDATA[Generate Biomedicines Inc. proved that enthusiasm hasn’t waned for TSLP as a target by pricing an IPO selling 25 million shares at $16 each for proceeds of $400 million. Generate’s lead compound is phase III-stage TSLP-targeting antibody GB-0895 and the company’s assigned Nasdaq ticker is GENB. The offering is expected to close on March 2.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729255</guid>
      <pubDate>Fri, 27 Feb 2026 12:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729255-tslp-still-plays-well-generates-400m-ipo</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Money/IPO-money.webp?t=1589580854" type="image/png" medium="image" fileSize="658149">
        <media:title type="plain">IPO money</media:title>
      </media:content>
    </item>
    <item>
      <title>Slate Medicines launches with focus on headache disorders</title>
      <description>
        <![CDATA[Slate Medicines Inc. has launched with $130 million in series A financing and a focus on advancing next-generation therapeutics for migraine and other headache disorders.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729036</guid>
      <pubDate>Wed, 25 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729036-slate-medicines-launches-with-focus-on-headache-disorders</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/Migraine-illustration.webp?t=1720189696" type="image/jpeg" medium="image" fileSize="134615">
        <media:title type="plain">Concept art for headache</media:title>
      </media:content>
    </item>
    <item>
      <title>Vesalic targeting toxic muscle exosomes in motor neuron diseases </title>
      <description>
        <![CDATA[Newco Vesalic Ltd. has formed to take forward research indicating extracellular vesicles secreted by skeletal muscle cells carry toxic payloads that are key drivers of motor neuron diseases, including amyotrophic lateral sclerosis. The discovery of this process, which is largely external to the brain and the central nervous system, has opened up new targeting possibilities, and Vesalic is now working on in vivo studies to demonstrate preclinical proof of concept.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729227</guid>
      <pubDate>Tue, 24 Feb 2026 09:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729227-vesalic-targeting-toxic-muscle-exosomes-in-motor-neuron-diseases</link>
      <media:content url="https://www.bioworld.com/ext/resources/Stock-images/Therapeutic-topics/Neurology/neuron-network.webp?t=1589299508" type="image/png" medium="image" fileSize="484029">
        <media:title type="plain">Neural network</media:title>
      </media:content>
    </item>
    <item>
      <title>SLAMF6 is suppressor of T-cell cancer immunity</title>
      <description>
        <![CDATA[SLAMF6 is an immune cell receptor whose function was not clear. Does it activate or inhibit cells? The results so far have been contradictory. Now, scientists at the Institut de Recherches Cliniques de Montréal have unveiled evidence that SLAMF6, a protein of the SLAM family that binds to copies of itself, is regulated by interactions between molecules of the same receptor within the same cell.]]>
      </description>
      <guid>http://www.bioworld.com/articles/729174</guid>
      <pubDate>Thu, 19 Feb 2026 08:00:00 -0500</pubDate>
      <link>https://www.bioworld.com/articles/729174-slamf6-is-suppressor-of-t-cell-cancer-immunity</link>
      <media:content url="https://www.bioworld.com/ext/resources/BWS/BWS-library/NIH-NIAID-T-Lymphocyte.webp?t=1715611906" type="image/png" medium="image" fileSize="958813">
        <media:title type="plain">Colorized scanning electron micrograph of a T lymphocyte.</media:title>
        <media:description type="plain">T lymphocyte. Credit: National Institute of Allergy and Infectious Diseases, NIH
</media:description>
      </media:content>
    </item>
  </channel>
</rss>
